Business Context and Reporting Period
Company: Faraday Future Intelligent Electric Inc. (FFAI)
Filing Type: Form 10-Q
Period Ended: September 30, 2025 (Q3 2025)
Business Overview: The Company designs and manufactures intelligent electric vehicles (FF 91, FF 92, and FX Series) and has recently expanded into a crypto-focused strategy via the acquisition of AIxCrypto Holdings, Inc. (AIXC). The Company operates primarily through its AI Electric Vehicle (AIEV) segment, with Life Sciences and Crypto segments currently immaterial to reporting.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $37 | $9 | $407 | $304 |
| Cost of Revenue | $34,256 | $21,453 | $82,549 | $63,110 |
| Gross Profit | $(34,219) | $(21,444) | $(82,142) | $(62,806) |
| Net Loss | $(222,187) | $(77,686) | $(357,141) | $(234,588) |
| Net Loss Per Share (Basic/Diluted) | $(1.55) | $(5.32) | $(3.31) | $(27.42) |
| Cash and Restricted Cash | $62,937 | $7,349 | $62,937 | $7,349 |
| Total Assets | $315,584 | $425,400 | $315,584 | $425,400 |
| Total Liabilities | $355,124 | $310,433 | $355,124 | $310,433 |
| Stockholders' Equity (Deficit) | $(39,540) | $114,967 | $(39,540) | $114,967 |
Liquidity: Cash balance increased to $62.9 million from $7.1 million at year-end 2024, driven by financing activities. However, the Company reports a negative working capital position of $121.2 million.
Material Changes vs. Prior Period
- Asset Impairment: Recorded a significant non-cash impairment charge of $138.5 million for the quarter (and nine months) ended September 30, 2025. This includes $130.0 million related to long-lived assets (tooling, machinery, equipment) and $8.5 million related to deposits. This was triggered by the elimination of federal EV tax credits, shifting focus from FF 91 to FF 92/FX programs, and macroeconomic uncertainty.
- Operating Expenses: Total operating expenses surged to $172.6 million in Q3 2025 from $3.8 million in Q3 2024, primarily due to the impairment charge. Excluding impairment, controllable operating expenses (R&D, S&M, G&A) increased due to FX Super One launch marketing and higher personnel costs.
- Revenue: Revenue increased to $37,000 in Q3 2025 from $9,000 in Q3 2024, driven by the sale of one vehicle under a co-creation arrangement. Automotive leasing revenue was negligible in the current quarter.
- Debt Settlement: Loss on settlement of notes payable decreased to $46.5 million in Q3 2025 from $59.1 million in Q3 2024, reflecting lower conversion volumes despite higher loss per dollar converted due to stock price fluctuations.
- Acquisition: Consolidated AIXC (formerly Qualigen Therapeutics) on September 29, 2025, for $30.0 million. AIXC is being rebranded as CXC10 to serve as a platform for crypto and Web3 initiatives.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year from the filing date due to recurring losses and negative operating cash flows. Continued operations depend on securing additional capital.
- Strategic Shift: The Company is pivoting from the FF 91 program to the FF 92 upgrade and the commercial production of the FX Super One. It is also launching an "EAI + Crypto" strategy via AIXC.
- Regulatory Risks: The Company, along with Global Co-CEO Yueting Jia and President Jerry Wang, received Wells Notices from the SEC in June 2025 regarding potential enforcement actions for alleged violations of anti-fraud provisions related to the 2021 PIPE and SPAC listing. Mr. Jia was temporarily excluded from oversight of finance and legal functions in August 2025.
- Internal Controls: The Company disclosed material weaknesses in internal control over financial reporting, including insufficient segregation of duties, lack of formal accounting policies, and ineffective IT general controls. Disclosure controls and procedures were deemed ineffective.
- Tariff Exposure: Significant reliance on China-based suppliers exposes the Company to elevated U.S. import tariffs, which could materially impact future manufacturing costs and unit economics.
- Financing: The Company relies heavily on SPA Portfolio Notes and convertible debt. While $55.6 million remains to be funded under existing commitments, these are subject to closing conditions including minimum share price requirements.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $62.9 million cash balance against the negative working capital of $121.2 million and ongoing burn rate to assess immediate liquidity risk.
- SPA Commitments: Confirm the status of the $55.6 million remaining to be funded under SPA Portfolio Notes and the likelihood of meeting minimum share price/volume closing conditions.
- SEC Investigation: Monitor the outcome of the SEC Wells Notices and the potential for enforcement actions, penalties, or officer bars against key executives.
- FX Super One Production: Validate timelines and capital requirements for the commercial production of the FX Super One, as this is the primary revenue driver for the future.
- Asset Valuation: Review the independent third-party valuation study supporting the $130 million impairment charge to ensure assets are not further overvalued.
- Internal Control Remediation: Assess the progress of the remediation plan for material weaknesses in internal controls, particularly regarding related party transactions and financial reporting.